表皮生长因子受体-2和P53及Ki67的表达状况对预测乳腺癌化疗敏感性的临床价值  

Value of expression of CerbB-2,P53,Ki67 in prediction of response to neoadjuvant chemotherapy in breast cancer

作　　者：廖丹[1] 姚和瑞[1] 陈焕清[2] 

机构地区：[1]中山大学附属第二医院肿瘤科,广州510120 [2]中山大学附属第二医院预防保健科,广州510120

出　　处：《中华临床医师杂志（电子版）》2010年第10期13-16,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：广东省科技计划项目(2008B030301092)

摘　　要：目的探讨表皮生长因子受体-2(CerbB-2)、P53和Ki67的表达状况对预测乳腺癌化疗敏感性的临床价值。方法检测86例乳腺癌患者瘤体组织CerbB-2、P53和Ki67的表达水平,观察每例患者新辅助化疗的疗效,比较CerbB-2、P53和Ki67不同表达水平的患者接受新辅助化疗的疗效差异。结果 CerbB-2阴性的乳腺癌患者对新辅助化疗的有效率为89.1%,明显好于CerbB-2阳性患者的51.6%;Ki67阳性的乳腺癌患者对新辅助化疗的有效率为82.8%,疗效好于Ki67阴性患者的60.7%;CerbB-2阴性并Ki67阳性患者对新辅助化疗的有效率为94.7%。P53表达状况对新辅助化疗的敏感性没有影响。结论乳腺癌患者瘤体组织CerbB-2阴性和Ki67阳性患者对新辅助化疗敏感性好,CerbB-2阴性并Ki67阳性可作为筛选乳腺癌临床化疗患者的生物学指标。Objective To evaluate the value of expression of CerbB-2,P53,Ki67 in prediction of the therapeutic effectiveness in breast cancer treated with neoadjuvant chemotherapy.Methods CerbB-2,P53,Ki67 protein express levels of the pretreatment biopsy tissues were detected in 86 patients with breast cancer.The relationships between CerbB-2,P53,Ki67 protein express levels and clinical response were analyzed respectively.Results The clinical response rates of the patients with CerbB-2 lowexpression were 89.1%,better than that（51.6%）of the patients with CerbB-2 overexpression; The clinical response rates of the patients with Ki67 overexpression were 82.8%,better than that（60.7%）of the patients with Ki67 lowexpression.The patients with CerbB-2 lowexpression and Ki67 overexpression show 94.7% clinical response rates.Expression level of P53 is not associated with the clinical respone rates.Conclusions CerbB-2 lowexpression and Ki67 overexpression are associated with hyper-reponse to neoadjuvant chemotherapy.They can serve as predictive markers to this regimen.

关 键 词：乳腺肿瘤 药物疗法 联合 受体 表皮生长因子 基因表达 基因 p53 KI-67抗原 

分 类 号：R737.9[医药卫生—肿瘤]